Cancer, Hearing Loss
Conditions
Brief summary
Over the last few years, there has been a considerable interest in the development of screening tools to assess the capability of elderly cancer patients to tolerate anti-cancer treatment. Therefore, the NCCN Guidelines in Senior Adult Oncology recommend an assessment of co-morbid conditions that are likely to interfere with cancer treatment and tolerability. As presbyacusis is common in an older population, elderly cancer patients are at high risk for social isolation and a reduced quality of life. Therefore, in this project the investigators aim to validatie uHear™ as a quick and reliable screening tool to screen for presbyacusisf in routine clinical oncology practice.
Interventions
None listed
Sponsors
General Hospital Groeninge
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
70 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Patients should have reached the age of 70 or more at enrolment * Histologically confirmed diagnosis of solid cancer or hematologic malignancy. All stages of cancer are eligible * Patients should be fluent in Dutch or French * Patients must receive their primary oncology care in the participating hospital * Patients should be cognitively capable of performing the audiology assessment * Patients should have signed informed consent
Exclusion criteria
* Patients who do not match the above inclusion criteria * Patients who are visiting the oncology clinic for a second opinion and do not wish to be treated in this clinic * Patients presenting with clinically diagnosed Ménière's disease, retrocochlear hearing loss, autoimmune inner ear disease, fluctuating hearing loss or a history of sudden sensory neural hearing loss * Patients who already have a hearing aid or a previously diagnosed hearing loss
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Validation of uHear™ as a screening tool to detect hearing loss in elderly cancer patients | Baseline |
Secondary
| Measure | Time frame |
|---|---|
| To determine the prevalence of presbyacusis in an elderly cancer population | Baseline |
| To compare objective and subjective hearing screening measures | Baseline |
| To measure hearing impairment in G8 positive patients compared with G8 negative patients | Baseline |
| To compare uHear™ with the Whispered Voice Test | Baseline |
| To evaluate the use of uHear™ as a measure to determine eligibility for cisplatin treatment in elderly cancer patients | Baseline |
Countries
Belgium
Outcome results
None listed